CARRINGTON LABORATORIES INC /TX/
8-A12G/A, 1998-10-29
PHARMACEUTICAL PREPARATIONS
Previous: CARRINGTON LABORATORIES INC /TX/, 8-K, 1998-10-29
Next: SEILER POLLUTION CONTROL SYSTEMS INC, 10-K, 1998-10-29




                                UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C.  20549

                               _______________

                                  FORM 8-A/A
                       (Post-Effective Amendment No. 1)


              FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
                       PURSUANT TO SECTION 12(b) OR (g)
                    OF THE SECURITIES EXCHANGE ACT OF 1934

                               _______________


                           CARRINGTON LABORATORIES, INC.
             (Exact name of registrant as specified in its charter)


             Texas                                 75-1435663
   (State of incorporation)          (I.R.S. employer identification number)
     2001 Walnut Hill Lane
          Irving, Texas                              75038
(Address of principal executive offices)          (Zip Code)      
                                                       
             

      SECURITIES TO BE REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

       If this Form relates to the registration of a class of securities
  pursuant to Section 12(b) of the Exchange Act and is effective pursuant
  to General Instruction A.(c), check the following box.  [  ]

       If this Form relates to the registration of a class of securities
  pursuant to Section 12(g) of the Exchange Act and is effective pursuant
  to General Instruction A.(d), check the following box:  [  ]

       The Securities Act registration statement file number to which this
  form relates:  (if applicable)

                                     None

      SECURITIES TO BE REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
                        Preferred Share Purchase Rights
                               (Title of Class)

                   
<PAGE>

  Item 1.  Description of Registrant's Securities to be Registered.

       The  following  information  supplements  and amends the description
  contained  in  the  Form  8-A  Registration Statement heretofore filed by
  Carrington  Laboratories,  Inc.  (the  "Company")  with  respect  to  the
  Preferred  Share  Purchase  Rights  (the  "Rights") issued by the Company
  pursuant  to  the  Rights  Agreement  dated as of September 19, 1991 (the
  "Rights  Agreement")  between the Company and Ameritrust Company National
  Association  ("Ameritrust"),  as Rights Agent.  Certain capitalized terms
  used  herein  and not otherwise defined herein have the meanings ascribed
  to them in the Rights Agreement.

       Subsequent  to  the  execution  of  the  Rights  Agreement,  KeyCorp
  Shareholder Services ("KeyCorp"), as successor in interest to Ameritrust,
  became  the successor Rights Agent under the Rights Agreement.  Effective
  October  21,  1998,  the  Company removed KeyCorp as the Rights Agent and
  appointed  American  Stock Transfer & Trust Company ("AST"), the transfer
  agent of the Company's Common Stock, to serve as successor Rights Agent.

       The  Company  and  AST, as successor Rights Agent, then entered into
  Amendment  No.  1  to Rights Agreement, dated and effective as of October
  21,  1998  (the  "Amendment"),  amending  the  Rights  Agreement  in  the
  following respects:

            (1)  Section  1(a)  of  the  Rights  Agreement  was  amended to
       provide  that if the Company's Board of Directors determines in good
       faith  that  a  person who acquires more than 20% of the outstanding
       Common  Shares  of  the  Company  and  thereby becomes an "Acquiring
       Person"  has done so inadvertently, and such person promptly divests
       a  sufficient  number of Common Shares to bring its ownership level
       below  20%, such person will not be deemed an "Acquiring Person" for
       purposes of the Rights Agreement.

            (2)  A  new  Section  7(e) was added to the Rights Agreement to
       allow  the Company to suspend the exercisability of the Rights for a
       period  of  up  to  90  days after the Distribution Date in order to
       prepare,  file  and have declared effective a registration statement
       under  the  Securities  Act  with  respect  to  the Preferred Shares
       issuable upon exercise of the Rights.
    
            (3)  A  new  Section  9(d) was added to the Rights Agreement to
       provide  procedures  for compensating holders of Rights issued under
       the  Rights  Agreement  in  the  event that the number of authorized
       Preferred  Shares  is  not  sufficient to permit the exercise of the
       Rights as provided in the Rights Agreement and the Company is unable
       to authorize additional Preferred Shares.
<PAGE>
            (4)  The  portion  of  Section  21 of the Rights Agreement that
       specifies the qualifications that a successor Rights Agent must meet
       was  amended  to  provide  that  a  successor Rights Agent must be a
       corporation  organized  and  doing  business  under  the laws of the
       United  States  or any state of the United States, in good standing,
       having  an  office  or  agency  in  any  state of the United States,
       authorized  under  such laws to exercise stock transfer or corporate
       trust  powers,  subject  to supervision or examination by federal or
       state authority, and having at the time of its appointment as Rights
       Agent a combined capital and surplus of at least $50 million, except
       that  the  principal  transfer  agent for the Company's Common Stock
       shall  be qualified to be Rights Agent notwithstanding the amount of
       its combined capital and surplus.

       The  Amendment  is  attached  hereto  as  Exhibit  4.  The foregoing
  description of the Amendment is qualified by reference to such Exhibit.

<PAGE>
  Item 2.  Exhibits.

       4.   Amendment  No.  1  to Rights Agreement, dated as of October 21,
            1998,  between Carrington Laboratories, Inc. and American Stock
            Transfer & Trust Company, as successor Rights Agent.


                                  SIGNATURE

       Pursuant  to  the  requirements  of  Section  12  of  the Securities
  Exchange  Act  of  1934,  as amended, the registrant has duly caused this
  Post-Effective  Amendment  No. 1 to Form 8-A Registration Statement to be
  signed on its behalf by the undersigned, thereto duly authorized.

                                CARRINGTON LABORATORIES, INC.




                                By: /s/ Carlton E. Turner                  
                                   Carlton E. Turner, Ph.D., D.Sc.
                                   President and Chief Executive Officer

  Date: October 28, 1998
<PAGE>

                              INDEX TO EXHIBITS


  Item
  Number            Exhibit

  4                 Amendment  No.  1  to  Rights  Agreement,  dated  as of
                    October 21, 1998, between Carrington Laboratories, Inc.
                    and   American  Stock  Transfer  &  Trust  Company,  as
                    successor Rights Agent.




                                  EXHIBIT 4


                       AMENDMENT NO. 1 TO RIGHTS AGREEMENT


     This  AMENDMENT  NO. 1 TO RIGHTS AGREEMENT ("AMENDMENT NO. 1"),  dated
  as of  October  21, 1998, between  CARRINGTON LABORATORIES, INC., a Texas
  corporation  (the  "Company"),  and  AMERICAN   STOCK  TRANSFER  &  TRUST
  COMPANY, as successor Rights Agent (the "Rights Agent"),

                                  WITNESSETH:

     WHEREAS,  the  Company  and  AMERITRUST COMPANY  NATIONAL  ASSOCIATION
  ("Ameritrust"), as Rights Agent, entered into a Rights Agreement dated as
  of September 19, 1991 (the "Rights Agreement"); and

     WHEREAS,  pursuant  to  Section  19 of  the  Rights Agreement, KeyCorp
  Shareholder  Services, as successor in interest to Ameritrust, became the
  successor Rights Agent under the Rights Agreement; and

     WHEREAS, pursuant  to  Section 21 of the Rights Agreement, the Company
  removed  KeyCorp Shareholder Services as the successor Rights Agent under
  the Rights Agreement, effective October 21, 1998; and

     WHEREAS,  pursuant  to  Sections 21 and 28  of  the  Rights Agreement,
  the Company  has  appointed  AMERICAN  STOCK  TRANSFER & TRUST COMPANY to
  serve  as  successor  Rights  Agent under the Rights Agreement, effective
  October 21, 1998; and

     WHEREAS, pursuant  to  Section 27 of the Rights Agreement, the Company
  desires to amend the Rights Agreement as set forth below;

     NOW, THEREFORE, the Rights Agreement is hereby amended as follows:

     Section 1.     Amendment  of  Section  1.   Section 1(a) of the Rights
  Agreement  is  amended by adding to the end of such section the following
  sentence:
          
     "Notwithstanding  the  foregoing,  if  the  Board  of Directors of the
     Company  determines in good faith that a Person who would otherwise be
     an "Acquiring Person," as defined pursuant to the foregoing provisions
     of  this  definition,  has  become such inadvertently, and such Person
     divests  as  promptly  as  practicable  a  sufficient number of Common
     Shares  of  the  Company  so  that  such  Person would no longer be an
     "Acquiring Person," as defined pursuant to the foregoing provisions of
     this  definition,  then  such  Person  shall  not  be  deemed to be an
     "Acquiring Person" for any purposes of this Agreement."
<PAGE>
     Section 2.     Amendment  of  Section  7.    Section  7  of the Rights
  Agreement is amended by adding thereto the following subsection (e):

          "(e) The  Company  may  temporarily suspend, for a period of time
     not  to  exceed  90  calendar  days  after  the Distribution Date, the
     exercisability   of  the  Rights  in  order  to  prepare  and  file  a
     Registration  Statement  under  the  Securities Act, on an appropriate
     form,  with  respect to the Preferred Shares purchasable upon exercise
     of  the  Rights  and  permit  such  Registration  Statement  to become
     effective;  provided,  however,  that  no such suspension shall remain
     effective  after,  and  the Rights shall without any further action by
     the  Company  or any other Person become exercisable immediately upon,
     the  effectiveness  of  such  Registration  Statement.   Upon any such
     suspension, the Company shall issue a public announcement stating that
     the  exercisability  of  the Rights has been temporarily suspended and
     shall  issue  a  further  public  announcement  at  such  time  as the
     suspension  is  no  longer  in  effect.  Notwithstanding any provision
     herein  to  the  contrary,  the Rights shall not be exercisable in any
     jurisdiction  if  the  requisite  qualification  under the Blue Sky or
     securities  laws  of such jurisdiction shall not have been obtained or
     the  exercise  of  the  Rights shall not be permitted under applicable
     law."
<PAGE>
     Section 3.     Amendment  of  Section  9.    Section  9  of the Rights
  Agreement is amended by  adding thereto the following subsection (d):

          "(d) In  the  event  that there shall not be sufficient Preferred
     Shares issued but not outstanding or authorized but unissued to permit
     the exercise or exchange of Rights in accordance with Section 11 or 24
     hereof,  as  the case may be, the Company covenants and agrees that it
     will  take all such action as may be necessary to authorize additional
     Preferred  Shares for issuance upon the exercise or exchange of Rights
     pursuant  to  Section  11  or 24 hereof, as the case may be; provided,
     however,  that  if the Company is unable to cause the authorization of
     additional  Preferred  Shares,  then  the Company shall, or in lieu of
     seeking  any  such  authorization,  the  Company  may,  to  the extent
     necessary  and  permitted  by  applicable  law  and  any agreements or
     instruments  in effect prior to the Distribution Date to which it is a
     party,  (i)  upon surrender of a Right, pay cash equal to the Purchase
     Price  in  lieu  of  issuing  Preferred  Shares  and requiring payment
     therefor,  (ii)  upon  due  exercise  of  a  Right  and payment of the
     Purchase  Price  for  each  Preferred  Share as to which such Right is
     exercised,  issue  equity securities having a value equal to the value
     of  the  Preferred  Shares  that  otherwise  would  have been issuable
     pursuant  to  Section 11 or 24 hereof, which value shall be determined
     by  a  nationally  recognized  investment banking firm selected by the
     Board  of  Directors  of  the Company, or (iii) upon due exercise of a
     Right and payment of the Purchase Price for each Preferred Share as to
     which  such  Right is exercised, distribute a combination of Preferred
     Shares,  cash  and/or  other  equity  and/or debt securities having an
     aggregate  value  equal  to  the  value  of  the Preferred Shares that
     otherwise  would  have  been  issuable  pursuant  to  Section 11 or 24
     hereof,  which  value  shall  be determined by a nationally recognized
     investment  banking  firm  selected  by  the Board of Directors of the
     Company.    To  the  extent that any legal or contractual restrictions
     (pursuant  to  agreements  or  instruments  in  effect  prior  to  the
     Distribution  Date  to  which  it is a party) prevent the Company from
     paying  the  full  amount  payable  in  accordance  with the foregoing
     sentence,  the  Company shall pay to holders of the Rights as to which
     such  payments are being made all amounts that are not then restricted
     on  a  pro  rata  basis as such payments become permissible under such
     legal  or  contractual restrictions until such payments have been paid
     in full."

     Section 4.     Amendment of Section 21.  The fifth sentence of Section
  21 of the Rights Agreement is amended to read in its entirety as follows:

     "Any  successor  Rights  Agent, whether appointed by the Company or by
     such  a  court,  shall  be  a corporation organized and doing business
     under the laws of the United States or any state of the United States,
     in  good  standing,  having  an  office  or agency in any state of the
     United  States,  which is authorized under such laws to exercise stock
     transfer  or  corporate  trust powers and is subject to supervision or
     examination by federal or state authority and which has at the time of
     its  appointment  as Rights Agent a combined capital and surplus of at
     least  $50  million;  provided,  however,  that the principal transfer
     agent  for the Common Shares shall be qualified to be the Rights Agent
     notwithstanding the amount of its combined capital and surplus."
<PAGE>
     Section 5.    Effectiveness.   This  AMENDMENT  NO.  1 shall be deemed
  effective  as  of October 21, 1998, as if executed by both parties hereto
  on  such  date.    Except  as  amended hereby, the Rights Agreement shall
  remain in full force and effect and shall be otherwise unaffected hereby.

     Section 6.     Miscellaneous.  This AMENDMENT NO. 1 shall be deemed to
  be  a  contract  made  under  the  laws of the State of Texas and for all
  purposes  shall  be governed by and construed in accordance with the laws
  of  such  state applicable to contracts to be made and performed entirely
  within such state.  This AMENDMENT NO. 1 may be executed in any number of
  counterparts,  each  of  which  shall for all purposes be deemed to be an
  original, and all such counterparts shall together constitute but one and
  the same instrument.  If any term, provision, covenant, or restriction of
  this AMENDMENT NO.1 is held by a court of competent jurisdiction or other
  authority  to be invalid, illegal, or unenforceable, the remainder of the
  terms,  provisions, covenants  and  restrictions  of this AMENDMENT NO. 1
  shall  remain  in  full force and effect and shall in no way be affected,
  impaired, or invalidated.

     IN WITNESS WHEREOF, the parties hereto have caused this  AMENDMENT NO.
  1 to  be duly executed as of the date first set forth above.


  CARRINGTON  LABORATORIES, INC.      AMERICAN STOCK TRANSFER & TRUST COMPANY


  By:  /s/  Carlton E. Turner              By:   /s/  Herbert J. Lemmer     
  Carlton E. Turner, Ph.D., D.Sc.          Herbert J. Lemmer
  President and Chief Executive Officer    Vice  President & General Counsel




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission